This tracker is no longer being regularly updated. Updated 01 July with new information on Paxlovid, Evusheld, molnupiravir, Regkirona and ivermectin. Build your own dashboard to track the coronavirus in places across the United States. Among all Californians, 72.3 are fully vaccinated, meaning they have either received both shots of a two. Whenever possible, we will describe how these therapeutics work against the dominant variants circulating throughout the world. So far, 79.9 of residents have received at least one dose, about 31.3 million people. The CDC emphasizes that travelers should make sure theyre up to date with their COVID-19 vaccines before taking a cruise, in addition to following their.

Therapeutics that are effective against one version of the virus, for example, may be significantly less effective or even ineffective against a new variant. Get all the latest news on COVID-19 vaccine developments from around the world with our coronavirus vaccine tracker. Cultivate a healthy, safe and welcoming community through exceptional public services, effective partnerships and dedicated. Regulators around the world have allowed many other additional treatments to be used on an emergency-use basis.Ī key ongoing focus in developing COVID-19 treatments will be the efficacy of therapeutics against current and emergent SARS-CoV-2 variants. An interactive web-based dashboard to track COVID-19 in real time.

Additionally, 107,490,375 people or 32 of the population have received a booster dose.

Overall, 223,035,566 people or 67 of the population are considered fully vaccinated. Evusheld (tixagevimab and cilgavimab AZD7442) has been authorized in several countries for use as pre-exposure prophylaxis. At least 261,591,428 people or 79 of the population have received at least one dose. A handful of therapeutics have been approved specifically to treat COVID-19, reduce its severity, or prevent it entirely.Īs of July 2022, those treatments include dexamethasone, Avigan (favilavir), Veklury (remdesivir) alone and in combination with Olumiant (baricitinib), Lagevrio (molnupiravir), Xevudy (sotrovimab), Regkirona (regdanvimab), Ronapreve (casirivimab and imdevimab), amubarvimab and romlusevimab (formerly BRII-196 and BRII-198), Actemra/RoActemra (tocilizumab), Paxlovid (nirmatrelvir + ritonavir), and Kineret (anakinra).

Nytimes vaccine tracker